Serum growth factor analysis in dry eye syndrome

Jay C. Bradley, Rachael H. Bradley, David L. Mccartney, Mark J Mannis

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: To perform a comprehensive serum growth factor analysis in dry eye syndrome patients and to compare this with matched controls. Methods: Six female dry eye syndrome patients and six age- and gender-matched controls were recruited. Whole blood was collected, allowed to clot and then centrifuged. Serum was extracted by using sterile technique. Enzyme-linked immunosorbent assays were performed to quantify serum growth factor levels. Results: Levels of transforming growth factor-beta 1 and 2 (TGF-β1 and β2), nerve growth factor (NGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), acidic and basic fibroblast growth factor (FGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor-AA, AB and BB (PDGF-AA, AB and BB), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF) were quantified, and statistical analysis was performed by using the Mann-Whitney U-test with the Bonferroni correction. Conclusions: No significant difference was found between serum growth factor levels in dry eye syndrome patients versus controls. Our study provides comprehensive analysis of serum growth factor levels in autologous serum eye drops produced from ocular surface disease patients. A knowledge of growth factor levels in serum may be important because of the increasing use of autologous serum eye drops in refractory ocular surface diseases and for an understanding of how topical serum may provide benefit.

Original languageEnglish (US)
Pages (from-to)717-720
Number of pages4
JournalClinical and Experimental Ophthalmology
Volume36
Issue number8
DOIs
StatePublished - 2008

Fingerprint

Dry Eye Syndromes
Statistical Factor Analysis
Intercellular Signaling Peptides and Proteins
Serum
Neurotrophin 3
Eye Diseases
Ophthalmic Solutions
Fibroblast Growth Factor 7
Glial Cell Line-Derived Neurotrophic Factor
Fibroblast Growth Factor 1
Hepatocyte Growth Factor
Brain-Derived Neurotrophic Factor
Nerve Growth Factor
Somatomedins
Fibroblast Growth Factor 2
Nonparametric Statistics
Epidermal Growth Factor
Transforming Growth Factor beta
Vascular Endothelial Growth Factor A
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anterior segment
  • Autologous serum
  • Dry eye syndrome
  • Growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Serum growth factor analysis in dry eye syndrome. / Bradley, Jay C.; Bradley, Rachael H.; Mccartney, David L.; Mannis, Mark J.

In: Clinical and Experimental Ophthalmology, Vol. 36, No. 8, 2008, p. 717-720.

Research output: Contribution to journalArticle

Bradley, Jay C. ; Bradley, Rachael H. ; Mccartney, David L. ; Mannis, Mark J. / Serum growth factor analysis in dry eye syndrome. In: Clinical and Experimental Ophthalmology. 2008 ; Vol. 36, No. 8. pp. 717-720.
@article{b8df3503e5e8459d8a0820070cb377bb,
title = "Serum growth factor analysis in dry eye syndrome",
abstract = "Background: To perform a comprehensive serum growth factor analysis in dry eye syndrome patients and to compare this with matched controls. Methods: Six female dry eye syndrome patients and six age- and gender-matched controls were recruited. Whole blood was collected, allowed to clot and then centrifuged. Serum was extracted by using sterile technique. Enzyme-linked immunosorbent assays were performed to quantify serum growth factor levels. Results: Levels of transforming growth factor-beta 1 and 2 (TGF-β1 and β2), nerve growth factor (NGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), acidic and basic fibroblast growth factor (FGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor-AA, AB and BB (PDGF-AA, AB and BB), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF) were quantified, and statistical analysis was performed by using the Mann-Whitney U-test with the Bonferroni correction. Conclusions: No significant difference was found between serum growth factor levels in dry eye syndrome patients versus controls. Our study provides comprehensive analysis of serum growth factor levels in autologous serum eye drops produced from ocular surface disease patients. A knowledge of growth factor levels in serum may be important because of the increasing use of autologous serum eye drops in refractory ocular surface diseases and for an understanding of how topical serum may provide benefit.",
keywords = "Anterior segment, Autologous serum, Dry eye syndrome, Growth factor",
author = "Bradley, {Jay C.} and Bradley, {Rachael H.} and Mccartney, {David L.} and Mannis, {Mark J}",
year = "2008",
doi = "10.1111/j.1442-9071.2008.01895.x",
language = "English (US)",
volume = "36",
pages = "717--720",
journal = "Clinical and Experimental Ophthalmology",
issn = "1442-6404",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Serum growth factor analysis in dry eye syndrome

AU - Bradley, Jay C.

AU - Bradley, Rachael H.

AU - Mccartney, David L.

AU - Mannis, Mark J

PY - 2008

Y1 - 2008

N2 - Background: To perform a comprehensive serum growth factor analysis in dry eye syndrome patients and to compare this with matched controls. Methods: Six female dry eye syndrome patients and six age- and gender-matched controls were recruited. Whole blood was collected, allowed to clot and then centrifuged. Serum was extracted by using sterile technique. Enzyme-linked immunosorbent assays were performed to quantify serum growth factor levels. Results: Levels of transforming growth factor-beta 1 and 2 (TGF-β1 and β2), nerve growth factor (NGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), acidic and basic fibroblast growth factor (FGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor-AA, AB and BB (PDGF-AA, AB and BB), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF) were quantified, and statistical analysis was performed by using the Mann-Whitney U-test with the Bonferroni correction. Conclusions: No significant difference was found between serum growth factor levels in dry eye syndrome patients versus controls. Our study provides comprehensive analysis of serum growth factor levels in autologous serum eye drops produced from ocular surface disease patients. A knowledge of growth factor levels in serum may be important because of the increasing use of autologous serum eye drops in refractory ocular surface diseases and for an understanding of how topical serum may provide benefit.

AB - Background: To perform a comprehensive serum growth factor analysis in dry eye syndrome patients and to compare this with matched controls. Methods: Six female dry eye syndrome patients and six age- and gender-matched controls were recruited. Whole blood was collected, allowed to clot and then centrifuged. Serum was extracted by using sterile technique. Enzyme-linked immunosorbent assays were performed to quantify serum growth factor levels. Results: Levels of transforming growth factor-beta 1 and 2 (TGF-β1 and β2), nerve growth factor (NGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), acidic and basic fibroblast growth factor (FGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor-AA, AB and BB (PDGF-AA, AB and BB), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF) were quantified, and statistical analysis was performed by using the Mann-Whitney U-test with the Bonferroni correction. Conclusions: No significant difference was found between serum growth factor levels in dry eye syndrome patients versus controls. Our study provides comprehensive analysis of serum growth factor levels in autologous serum eye drops produced from ocular surface disease patients. A knowledge of growth factor levels in serum may be important because of the increasing use of autologous serum eye drops in refractory ocular surface diseases and for an understanding of how topical serum may provide benefit.

KW - Anterior segment

KW - Autologous serum

KW - Dry eye syndrome

KW - Growth factor

UR - http://www.scopus.com/inward/record.url?scp=58149359046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149359046&partnerID=8YFLogxK

U2 - 10.1111/j.1442-9071.2008.01895.x

DO - 10.1111/j.1442-9071.2008.01895.x

M3 - Article

VL - 36

SP - 717

EP - 720

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

SN - 1442-6404

IS - 8

ER -